Difference between revisions of "Part:BBa K2872019"
Line 83: | Line 83: | ||
===Reference=== | ===Reference=== | ||
− | [1]. Janice S. Chen, Enbo Ma, Lucas B. Harrington, Maria Da Costa, Xinran Tian, Joel M. Palefsky and Jennifer A. Doudna. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360, 436-439 (2018)< | + | [1]. Janice S. Chen, Enbo Ma, Lucas B. Harrington, Maria Da Costa, Xinran Tian, Joel M. Palefsky and Jennifer A. Doudna. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360, 436-439 (2018)<br> |
− | [2]. Xiong Ding, Kun Yin, Ziyue Li, Rajesh V. Lalla, Enrique Ballesteros, Maroun M. Sfeir and Changchun Liu. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. Nature Communications, 11, 4711(2020)< | + | [2]. Xiong Ding, Kun Yin, Ziyue Li, Rajesh V. Lalla, Enrique Ballesteros, Maroun M. Sfeir and Changchun Liu. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. Nature Communications, 11, 4711(2020)<br> |
[3]. Parinaz Fozouni, Sungmin Son, María Díaz de León Derby, Gavin J Knott, Carley N Gray, Michael V D'Ambrosio, Chunyu Zhao, Neil A Switz, G. Renuka Kumar, Stephanie I Stephens et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 184, 323–333(2021)<br> | [3]. Parinaz Fozouni, Sungmin Son, María Díaz de León Derby, Gavin J Knott, Carley N Gray, Michael V D'Ambrosio, Chunyu Zhao, Neil A Switz, G. Renuka Kumar, Stephanie I Stephens et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 184, 323–333(2021)<br> |
Revision as of 09:15, 21 October 2021
Cas12a protein
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 1198
Illegal PstI site found at 1696
Illegal PstI site found at 3403 - 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 1198
Illegal PstI site found at 1696
Illegal PstI site found at 3403 - 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 938
Illegal BglII site found at 1271
Illegal BglII site found at 1841
Illegal BglII site found at 2108
Illegal BglII site found at 2729 - 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 1198
Illegal PstI site found at 1696
Illegal PstI site found at 3403 - 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 1198
Illegal PstI site found at 1696
Illegal PstI site found at 3403
Illegal NgoMIV site found at 1000
Illegal NgoMIV site found at 1999
Illegal NgoMIV site found at 2701 - 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 1329
Illegal SapI.rc site found at 1389
Part Information
This part was synthesized using Cas12a DNA coding sequence from pY016 (pcDNA3.1-hLbCpf1) plasmid (Addgene plasmid # 69988) [1]
Biology and Usage
Cas12a is a programmable DNA endonuclease guided by a single guide RNA (gRNA) and can be used in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems. RNA-guided DNA binding unleashes indiscriminate single-stranded DNA (ssDNA) cleavage activity by Cas12a that completely degrades ssDNA molecules [2]
- Targeting requires a gRNA complementary to the target site as well as a 5' TTTN protospacer adjacent motif (PAM) on the DNA strand opposite the target sequence.
- Cleavage occurs ~18 bases 3' of the PAM and leaves 5' overhanging ends.
- Cas12 a relies on a short (40-44 base) guide RNA to initiate DNA degradation.
- Cas12a is active from 16 to 48°C and maintains activity at lower temperatures than the Acidaminococcus orthologs, permitting editing in ectothermic organisms such as zebra fish and xenopus.
- High concentration liquid format can be used for microinjection, electroporation and lipofection [3]
There are 2 classes of effectors in the microbial adaptive immune system; class 1 effectors utilize multi-protein complexes, whereas class 2 effectors rely on single-component effector proteins such as the well-characterized Cas9. Cas12a (Cpf1) is a putative class 2 CRISPR effector which mediates robust DNA interference with features distinct from Cas9. Cpf1 is a single RNA-guided endonuclease lacking tracrRNA, and it utilizes a T-rich protospacer-adjacent motif. Moreover, Cpf1 cleaves DNA via a staggered DNA double-stranded break. We chose Lachnospiraceae bacterium ND2006 Cpf1 (LbCpf1) -along with Acidaminococcus- because it was found to have efficient genome-editing activity in human cells. [4]
Source
Lachnospiraceae bacterium ND2006
References
[1] Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F. Cell. 2015 Sep 23. pii: S0092-8674(15)01200-3. doi: 10.1016/j.cell.2015.09.038. 10.1016/j.cell.2015.09.038 PubMed 26422227
[2]
Chen, J. S., Ma, E., Harrington, L. B., Costa, M. D., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018, April 27). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Retrieved from http://science.sciencemag.org/content/360/6387/436
[3] Biolabs, N. E. (n.d.). EnGen® Lba Cas12a (Cpf1). Retrieved from https://international.neb.com/products/m0653-engen-lba-cas12a-cpf1#Product Information_Notes
[4] Lassner, M. (2017). Faculty of 1000 evaluation for Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. F1000 - Post-publication Peer Review of the Biomedical Literature. doi:10.3410/f.725812264.793537694
iGEM Gifu 2021_Contribution
Group: iGEM Gifu 2021
Author: Yuichiro IKAGAWA, Kyoka SATO
Introduction
Cas12a recognizes and cleaves the target sequence of dsDNA depending on the target sequence and the T-rich PAM sequence. At this time, Cas12a exhibits collateral cleavage activity that indiscriminately cleaves the surrounding ssDNA. [1] CRISPR-AIOD assay, in which two different gRNAs are added, can improve the sensitivity. [2] The improvement of sensitivity by adding two different gRNAs has also been confirmed by an assay using Cas13a. [3]
Mechanism
Generally, in assays using a single gRNA, Cas is activated by the binding of a single Cas-gRNA complex to a single target DNA molecule. On the other hand, when two different gRNAs are introduced, two Cas-gRNA complexes bind to a single target DNA molecule, resulting in the activation of two Cas molecules. Since the number of Cas molecules activated per target molecule is doubled, sensitivity is expected to be improved [2], [3].
Design
In the Cas12a-based CRISPR-AIOD assay, two target sequences are first set up on the DNA to be detected as targets. Different from the usual gRNA design, these two sequences are not restricted by the PAM sequence, but they must be close to each other. Next, two types of gRNAs are designed based on the set sequences, and primers that can bind upstream and downstream of the two target sites are designed. Finally, by adding the designed two types of gRNAs and primers together with recombinase polymerase amplification (RPA) reagent for target DNA, one-pot and highly sensitive detection becomes possible. As a result of introducing two types of gRNAs, it has been reported that a lower copy of DNA can be detected than when a single gRNA is added. [2]
When designing a gRNA with Cas13a, two target sequences on the RNA to be detected are set in the same way. In contrast to Cas12a, which does not require PAM to be taken into account when designing, in Cas13a, both gRNAs to be designed are restricted by protospacer-flanking site (PFS). Studies have shown that simultaneous introduction of the two designed gRNAs and Cas13a is possible even with low-copy RNAs, and the amount of signal detected per time has been improved. [3]
Figure 1.
Figure 2.
Reference
[1]. Janice S. Chen, Enbo Ma, Lucas B. Harrington, Maria Da Costa, Xinran Tian, Joel M. Palefsky and Jennifer A. Doudna. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360, 436-439 (2018)
[2]. Xiong Ding, Kun Yin, Ziyue Li, Rajesh V. Lalla, Enrique Ballesteros, Maroun M. Sfeir and Changchun Liu. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay. Nature Communications, 11, 4711(2020)
[3]. Parinaz Fozouni, Sungmin Son, María Díaz de León Derby, Gavin J Knott, Carley N Gray, Michael V D'Ambrosio, Chunyu Zhao, Neil A Switz, G. Renuka Kumar, Stephanie I Stephens et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 184, 323–333(2021)